Effects of sigma receptor ligands on psychiatric disorders

Hiroyuki Kamei, Yukihiro Noda, Toshitaka Nabeshima, Kiyofumi Yamada

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

It has recently been suggested that sigma receptors are involved in psychiatric disorders. Sigma1 receptor antagonists are effective in animal models of positive symptoms, cognitive deficit and disruption of prepulse inhibition in schizophrenia. They also inhibit the development and expression of the conditioned place preference induced by cocaine. On the other hand, sigma1 receptor agonists reduce the immobility time in the forced swimming and tail suspension tests. Furthermore, sigma1 receptor agonists attenuate the conditioned fear stress (CFS) response (which is not attenuated by typical anxiolytics or antidepressants) in rodents. The attenuating effects are mediated through sigma1 receptors, which are closely related to the mesolimbic dopaminergic systems. Sigma1 receptor agonists also have anti-amnesic effects in various experimental models. Neurosteroids such as dehydroepiandrosterone sulfate and pregnenolone sulfate attenuate the CFS response and have anti-amnesic effects, the effects being mediated via sigma1 receptors. These findings suggest that sigma receptors are novel potential targets for the treatment of psychiatric disorders such as schizophrenia, drug abuse, depression and dementia.

Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalJapanese Journal of Neuropsychopharmacology
Volume23
Issue number5
Publication statusPublished - 01-10-2003

Fingerprint

sigma Receptors
Fear
Psychiatry
Schizophrenia
Ligands
Hindlimb Suspension
Neurobehavioral Manifestations
Dehydroepiandrosterone Sulfate
Anti-Anxiety Agents
Cocaine
Antidepressive Agents
Substance-Related Disorders
Neurotransmitter Agents
Dementia
Rodentia
Theoretical Models
Animal Models
Depression
Therapeutics
Prepulse Inhibition

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kamei, Hiroyuki ; Noda, Yukihiro ; Nabeshima, Toshitaka ; Yamada, Kiyofumi. / Effects of sigma receptor ligands on psychiatric disorders. In: Japanese Journal of Neuropsychopharmacology. 2003 ; Vol. 23, No. 5. pp. 187-196.
@article{d593b63f3141463c9a89ecd97fb52daa,
title = "Effects of sigma receptor ligands on psychiatric disorders",
abstract = "It has recently been suggested that sigma receptors are involved in psychiatric disorders. Sigma1 receptor antagonists are effective in animal models of positive symptoms, cognitive deficit and disruption of prepulse inhibition in schizophrenia. They also inhibit the development and expression of the conditioned place preference induced by cocaine. On the other hand, sigma1 receptor agonists reduce the immobility time in the forced swimming and tail suspension tests. Furthermore, sigma1 receptor agonists attenuate the conditioned fear stress (CFS) response (which is not attenuated by typical anxiolytics or antidepressants) in rodents. The attenuating effects are mediated through sigma1 receptors, which are closely related to the mesolimbic dopaminergic systems. Sigma1 receptor agonists also have anti-amnesic effects in various experimental models. Neurosteroids such as dehydroepiandrosterone sulfate and pregnenolone sulfate attenuate the CFS response and have anti-amnesic effects, the effects being mediated via sigma1 receptors. These findings suggest that sigma receptors are novel potential targets for the treatment of psychiatric disorders such as schizophrenia, drug abuse, depression and dementia.",
author = "Hiroyuki Kamei and Yukihiro Noda and Toshitaka Nabeshima and Kiyofumi Yamada",
year = "2003",
month = "10",
day = "1",
language = "English",
volume = "23",
pages = "187--196",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "5",

}

Effects of sigma receptor ligands on psychiatric disorders. / Kamei, Hiroyuki; Noda, Yukihiro; Nabeshima, Toshitaka; Yamada, Kiyofumi.

In: Japanese Journal of Neuropsychopharmacology, Vol. 23, No. 5, 01.10.2003, p. 187-196.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Effects of sigma receptor ligands on psychiatric disorders

AU - Kamei, Hiroyuki

AU - Noda, Yukihiro

AU - Nabeshima, Toshitaka

AU - Yamada, Kiyofumi

PY - 2003/10/1

Y1 - 2003/10/1

N2 - It has recently been suggested that sigma receptors are involved in psychiatric disorders. Sigma1 receptor antagonists are effective in animal models of positive symptoms, cognitive deficit and disruption of prepulse inhibition in schizophrenia. They also inhibit the development and expression of the conditioned place preference induced by cocaine. On the other hand, sigma1 receptor agonists reduce the immobility time in the forced swimming and tail suspension tests. Furthermore, sigma1 receptor agonists attenuate the conditioned fear stress (CFS) response (which is not attenuated by typical anxiolytics or antidepressants) in rodents. The attenuating effects are mediated through sigma1 receptors, which are closely related to the mesolimbic dopaminergic systems. Sigma1 receptor agonists also have anti-amnesic effects in various experimental models. Neurosteroids such as dehydroepiandrosterone sulfate and pregnenolone sulfate attenuate the CFS response and have anti-amnesic effects, the effects being mediated via sigma1 receptors. These findings suggest that sigma receptors are novel potential targets for the treatment of psychiatric disorders such as schizophrenia, drug abuse, depression and dementia.

AB - It has recently been suggested that sigma receptors are involved in psychiatric disorders. Sigma1 receptor antagonists are effective in animal models of positive symptoms, cognitive deficit and disruption of prepulse inhibition in schizophrenia. They also inhibit the development and expression of the conditioned place preference induced by cocaine. On the other hand, sigma1 receptor agonists reduce the immobility time in the forced swimming and tail suspension tests. Furthermore, sigma1 receptor agonists attenuate the conditioned fear stress (CFS) response (which is not attenuated by typical anxiolytics or antidepressants) in rodents. The attenuating effects are mediated through sigma1 receptors, which are closely related to the mesolimbic dopaminergic systems. Sigma1 receptor agonists also have anti-amnesic effects in various experimental models. Neurosteroids such as dehydroepiandrosterone sulfate and pregnenolone sulfate attenuate the CFS response and have anti-amnesic effects, the effects being mediated via sigma1 receptors. These findings suggest that sigma receptors are novel potential targets for the treatment of psychiatric disorders such as schizophrenia, drug abuse, depression and dementia.

UR - http://www.scopus.com/inward/record.url?scp=0242626719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242626719&partnerID=8YFLogxK

M3 - Review article

C2 - 14653224

AN - SCOPUS:0242626719

VL - 23

SP - 187

EP - 196

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 5

ER -